Solaxa Announces Phase 3 Clinical Trial for Spinocerebellar Ataxia Type 27B
Solaxa Announces Phase 3 Clinical Trial for Spinocerebellar Ataxia Type 27B Bethesda, MD — March 28, 2025 – Solaxa Inc., […]
Press
Press
Solaxa Inc. Announces FDA Clearance of IND Application for SLX-100
Solaxa Inc. Announces FDA Clearance of IND Application for SLX-100 Bethesda, MD; January 6, 2024 – Solaxa Inc. announces today
Press
Solaxa Inc. Collaborates with National Ataxia Foundation
Solaxa Inc. Collaborates with National Ataxia Foundation Bethesda, MD and Minneapolis, MN; September 25, 2024 – On International Ataxia Awareness
Solaxa Inc. Appoints Kerry Clem as Chief Commercial Officer
Solaxa Inc. Appoints Kerry Clem as Chief Commercial Officer Bethesda, MD; August 19, 2024 – Solaxa Inc. announces that Kerry
U.S. Food and Drug Administration Grants Orphan Drug Designation to Solaxa Inc.
U.S. Food and Drug Administration Grants Orphan Drug Designation to Solaxa Inc. Bethesda, MD; July 26, 2024 – Solaxa Inc.
TEDCO Announces SSBCI Investment in Solaxa Inc.
TEDCO Announces SSBCI Investment in Solaxa Inc. Maryland-based biopharmaceutical company receives funding from TEDCO’s Venture Funds COLUMBIA, Md., (July 23,
Maryland Tech Council Announces Winners of 2024 ICON Awards
The Maryland Tech Council (MTC), the largest technology and life sciences trade association in the state, today announced the winners
Solaxa chosen as an 8th Annual BHCR Crab Trap Winner
Rockville, Maryland – September 13, 2023 – BioHealth Innovation, Inc. (BHI), a leading regional innovation intermediary, is thrilled to announce
Researchers to study how drug can be repurposed to assess nerve injuries
Researchers at Penn State College of Medicine and Penn State Health Milton S. Hershey Medical Center are leading a clinical trial to evaluate whether
Solaxa Inc. Appoints Amy Chappel, MD, FAAN as Chief Medical Officer
Solaxa Inc. Appoints Amy Chappel, MD, FAAN as Chief Medical Officer Bethesda, MD; January 1, 2024 – Solaxa Inc. announces